Nothing Special   »   [go: up one dir, main page]

Jiang et al., 2022 - Google Patents

Head-to-head comparison of different blood collecting tubes for quantification of Alzheimer's disease biomarkers in plasma

Jiang et al., 2022

View HTML
Document ID
6260364128868053476
Author
Jiang L
Ding X
Wang W
Yang X
Li T
Lei P
Publication year
Publication venue
Biomolecules

External Links

Snippet

To examine whether the type of blood collection tubes affects the quantification of plasma biomarkers for Alzheimer's disease analyzed with a single-molecule array (Simoa), we recruited a healthy cohort (n= 34, 11 males, mean age= 28.7±7.55) and collected plasma in …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Health care, e.g. hospitals; Social work
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/01—Social networking
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light

Similar Documents

Publication Publication Date Title
Polyakova et al. Stability of BDNF in human samples stored up to 6 months and correlations of serum and EDTA-plasma concentrations
Yilmaz et al. Targeted metabolic profiling of urine highlights a potential biomarker panel for the diagnosis of Alzheimer’s disease and mild cognitive impairment: a pilot study
Abate et al. A conformation variant of p53 combined with machine learning identifies Alzheimer disease in preclinical and prodromal stages
Olesova et al. A novel UHPLC-MS method targeting urinary metabolomic markers for autism spectrum disorder
De Silva et al. Urinary biomarkers of renal injury KIM-1 and NGAL: reference intervals for healthy pediatric population in Sri Lanka
Hong et al. High-density lipoprotein changes in Alzheimer’s disease are APOE genotype-specific
Jiang et al. Head-to-head comparison of different blood collecting tubes for quantification of Alzheimer’s disease biomarkers in plasma
Halbgebauer et al. Neurochemical monitoring of traumatic brain injury by the combined analysis of plasma beta-synuclein, NfL, and GFAP in polytraumatized patients
Almashjary et al. Reticulocyte hemoglobin-equivalent potentially detects, diagnoses and discriminates between stages of iron deficiency with high sensitivity and specificity
Marzuillo et al. Acute kidney injury in children with acute appendicitis
Pereira et al. Pre-frailty and frailty in dialysis and pre-dialysis patients: a systematic review of clinical and biochemical markers
Ehtewish et al. Blood-Based Proteomic Profiling Identifies Potential Biomarker Candidates and Pathogenic Pathways in Dementia
Sung et al. based detection device for Alzheimer’s disease—detecting β-amyloid peptides (1–42) in human plasma
Oner et al. High Homocysteine Levels Are Associated with Cognitive Impairment in Patients Who Recovered from COVID-19 in the Long Term
Martínez-Dubarbie et al. Influence of Physiological Variables and Comorbidities on Plasma Aβ40, Aβ42, and p-tau181 Levels in Cognitively Unimpaired Individuals
Gambino et al. The Role of TAR DNA Binding Protein 43 (TDP-43) as a CandiDate Biomarker of Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis
Garzelli et al. Secondary S100B protein increase following brain arteriovenous malformation rupture is associated with cerebral infarction
Oosterveld et al. CSF biomarkers reflecting protein pathology and axonal degeneration are associated with memory, attentional, and executive functioning in early-stage parkinson′ s disease
Mroczek et al. Cerebrospinal fluid proteome alterations associated with neuropsychiatric symptoms in cognitive decline and Alzheimer’s disease
Barba et al. Specific cerebrospinal fluid SerpinA1 isoform pattern in Alzheimer’s disease
Gubari et al. The relationship between serum concentrations of pro-and anti-inflammatory cytokines and nutritional status in patients with traumatic head injury in the Intensive Care Unit
Kron et al. The changes of cholesterol Profile at the different insulin resistance range in the Czech Republic
Yoshihara et al. Cerebrospinal fluid protein concentration in healthy older Japanese volunteers
Duda et al. Plasma neutrophil gelatinase-associated lipocalin is useful for predicting mortality in critically ill patients
Lehmann et al. Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer’s Disease Continuum